Singapore markets close in 4 hours 6 minutes

Cellectis S.A. (CLLS)

NasdaqGM - NasdaqGM Delayed price. Currency in USD
Add to watchlist
2.0300-0.1300 (-6.02%)
At close: 04:00PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close2.1600
Open2.1100
Bid0.0000 x 0
Ask0.0000 x 0
Day's range2.0200 - 2.1200
52-week range0.9628 - 3.7735
Volume11,746
Avg. volume56,989
Market cap209.561M
Beta (5Y monthly)3.20
PE ratio (TTM)N/A
EPS (TTM)-1.3700
Earnings date28 May 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est7.00
  • Zacks

    Regenxbio (RGNX) Surges 18.3%: Is This an Indication of Further Gains?

    Regenxbio (RGNX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

  • Zacks

    Down -22.78% in 4 Weeks, Here's Why You Should You Buy the Dip in Cellectis (CLLS)

    Cellectis (CLLS) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

  • GlobeNewswire

    Monthly information on share capital and company voting rights

    (Article 223-16 of General Regulation of the French financial markets authority) PARIS, July 05, 2024 (GLOBE NEWSWIRE) -- Listing market: Euronext Growth ISIN code: FR0010425595 DateTotal number of shares in the capitalTotal number of voting rights06/30/2024100,093,63588,029,364 For further information on Cellectis, please contact: Media contact: Pascalyne Wilson, Director, Communications, +33 (0)7 76 99 14 33, media@cellectis.com Patricia Sosa Navarro, Chief of Staff to the CEO, +33 (0)7 76 77